Early-Onset Type 2 Diabetes Doubles in Young Swedes
Early-Onset Type 2 Diabetes Surges in Sweden: A Growing Public Health Crisis
Stockholm, Sweden – July 9, 2025 – A groundbreaking study published today in teh European Journal of Public Health reveals a dramatic and concerning rise in early-onset Type 2 Diabetes (T2D) in Sweden, posing a significant threat to public health and the nation’s workforce. The research,led by Sofia Carlsson at the Karolinska Institutet,highlights a near doubling of prevalence and incidence of T2D diagnosed in individuals aged 23-39 years over the study period,with projections indicating a continued upward trend through 2050.
The Alarming Rise of Early-Onset T2D
the study, which analyzed data from 2000 to 2021, recorded a staggering 529,785 new cases of T2D, with 24,210 of these classified as early-onset. The prevalence of early-onset T2D more than doubled, climbing from 0.27% to 0.64%,while incidence surged from 54 to 107 cases per 100,000 person-years.
Key Findings: A deep Dive into the Data
Accelerated Incidence in Younger Adults: The incidence of early-onset T2D saw a especially rapid increase in the youngest age bracket studied (23-29 years) compared to the oldest (35-39 years), with a 6.7% rise versus 3.6%. This trend was notably more pronounced among women.
Disparities in Prevalence and Incidence: Individuals born outside Europe exhibited higher rates of both early-onset T2D prevalence and incidence compared to those born within Europe. Furthermore, the study found that individuals with only primary education were more likely to develop early-onset T2D than those with higher educational qualifications.
Projected Future Burden: If current trends persist, the prevalence of early-onset T2D is projected to reach a concerning 3.22% by 2050. Women are expected to be disproportionately affected, with projected prevalence reaching 4.29% compared to 2.20% for men.
The Far-Reaching Impact of Early-Onset T2D
The authors of the study emphasize the profound implications of this escalating health issue. “The rise of early-onset T2D in Sweden signals an emerging threat to public health, as these patients have a high risk of complications and may face shortened life expectancy,” the researchers stated.
Impact on Prime Years
The study underscores that early-onset T2D affects individuals during their most productive years. “As early-onset T2D affects individuals during their prime working, childbearing, and child-raising years, its impact is highly likely to be more far-reaching than T2D diagnosed later in life,” they added. this means a greater burden on healthcare systems and a significant loss of economic productivity.
Methodological Approach and Limitations
The study’s methodology involved calculating the prevalence and incidence of T2D and early-onset T2D,stratifying the data by sex,region of birth,and education level.Prevalence projections for early-onset T2D through 2050 were generated by applying the 2021 age- and sex-standardized prevalence rates to official population forecasts.
Acknowledging Study Constraints
The researchers noted several limitations. They were unable to analyze trends among individuals younger than 23 years. Additionally, the absence of data on parental country of origin prevented an assessment of T2D incidence in children of immigrants. A further limitation identified was that women were subjected to stricter diagnostic criteria, requiring prescriptions for metformin plus an additional glucose-lowering drug to rule out polycystic ovary syndrome. This may have led to an underestimation of early-onset T2D prevalence in women.
funding and Disclosures
This research was supported by grants from the Swedish Research Council, the Swedish Diabetes Foundation, and the Strategic Research Area for Diabetes at Karolinska Institutet. The authors declared no relevant conflicts of interest.
Source: This study was led by Sofia Carlsson, institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. It was published online on July 09, 2025, in the European Journal of public Health*.